Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine Pathology
Published in: Endocrine Pathology 1/2016

01-03-2016

Non-Coding RNAs in Thyroid Cancer

Authors: Ranran Zhang, Heather Hardin, Jidong Chen, Zhenying Guo, Ricardo V. Lloyd

Published in: Endocrine Pathology | Issue 1/2016

Login to get access

Abstract

Non-coding (nc)RNAs are divided into small ncRNAs and long ncRNAs (lncRNAs). MicroRNAs (miRNAs) are small ncRNAS which are around 22 nucleotides in length that mediate post-transcriptional gene silencing. LncRNAs are greater than 200 bp in length. Each ncRNA can have multiple targets and can be regulated by multiple genetic factors. Because ncRNAs are not translated into proteins, they can only be detected at the nucleic acid level by in situ hybridization, by RT-PCR, or by sequencing which makes their detection more challenging in the routine pathology laboratory. A great deal of new information has accumulated about miRNAs in thyroid tissues during the past decade. Some of these studies have shown that deregulation of miRNAs may be useful in diagnostic pathology. Information about the role of lncRNA in the development of thyroid tumors is in the early stages of development, but new information is accumulating rapidly. In this review, we will discuss the recent progress in our understanding of the relationship between ncRNAs and the development of thyroid cancers and the potential uses of ncRNAs in the diagnosis and prognosis of thyroid tumors.
Literature
1.
Irminger-Finger I, Kargul J, Laurent GJ (2014) Non-coding RNAs: a novel level of genome complexity. Int J Biochem Cell Biol 54:286.CrossRefPubMed
2.
Amaral PP, Dinger ME, Mercer TR, Mattick JS (2008) The eukaryotic genome as an RNA machine. Science (80-) 319:1787–1789.CrossRefPubMed
3.
Venkatesh T, Suresh PS, Tsutsumi R (2015) Non-coding RNAs: functions and applications in endocrine-related cancer. Mol Cell Endocrinol 416:88–96.CrossRefPubMed
4.
5.
Kun Á, Szilágyi A, Könnyű B, Boza G, Zachar I, Szathmáry E (2015) The dynamics of the RNA world: insights and challenges. Ann N Y Acad Sci 1341:75–95.CrossRefPubMed
6.
7.
8.
Almeida MI, Reis RM, Calin GA (2011) MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res 717:1–8.CrossRefPubMed
9.
Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS (2010) Non-coding RNAs: regulators of disease. J Pathol 220:126–139.CrossRefPubMed
10.
Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10:155–159.CrossRefPubMed
11.
12.
Vester B, Wengel J (2004) LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 43:13233–13241.CrossRefPubMed
13.
Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ, Luo Y (2012) RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 14:22–29.PubMedCentralCrossRefPubMed
14.
Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, Ma T, Chen W, Han S, Jing X, Cao X, Wang X, Chandler B, Yan W, Siddiqui J, Kunju LP, Dhanasekaran SM, Pienta KJ, Feng FY, Chinnaiyan AM (2013) The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 45:1392–1398.PubMedCentralCrossRefPubMed
15.
Guo Z, Hardin H, Montemayor-Garcia C, Asioli S, Righi A, Maletta F, Sapino A, Lloyd R V (2015) In situ hybridization analysis of miR-146b-5p and miR-21 in thyroid nodules: diagnostic implications. Endocr Pathol 26:157–163.CrossRefPubMed
16.
Huang W, Eickhoff JC, Mehraein-Ghomi F, Church DR, Wilding G, Basu HS (2015) Expression of spermidine/spermine N1-acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis. Prostate 75:1150–1159.CrossRefPubMed
17.
Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, Musolino C (2012) Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer. Int J Oncol 41:1897–1912.PubMed
18.
Regazzi R, Guay C, Regazzi R (2013) Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol 9:513–52186.CrossRefPubMed
19.
Alix - Panabì eres C, Schwarzenbach H, Pantel K (2012) Circulating tumor cells and circulating tumor DNA. Annu Rev Med 63:199–215CrossRef
20.
Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, Frio TR, Pierron EG, Eline Callens C, Bieche I, Saliou A, Madic J, Rouleau E, Ement Bidard F-C, Lantz O, Stern M-H, Le Tourneau C, Pierga J-Y (2015) Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 9:783–790.CrossRefPubMed
21.
Nikiforov YE, Nikiforova MN (2011) Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7:569–580.CrossRefPubMed
22.
23.
24.
25.
Jonas S, Izaurralde E (2015) Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet 16:421–433.CrossRefPubMed
26.
Pennelli G, Galuppini F, Barollo SB, Cavedon E, Bertazza L, Fassan M, Guzzardo VB, Rosa Pelizzo M, Rugge M, Mian C (2015) The PDCD4/miR-21 pathway in medullary thyroid carcinoma. Hum Pathol 46:50–57.CrossRefPubMed
27.
Zhang J, Yang Y, Liu Y, Fan Y, Liu Z, Wang X, Yuan Q, Yin Y, Yu J, Zhu M, Zheng J, Lu X (2014) MicroRNA-21 regulates biological behaviors in papillary thyroid carcinoma by targeting programmed cell death 4. J Surg Res 189:68–74.CrossRefPubMed
28.
29.
Mancikova V, Castelblanco E, Pineiro-Yanez E, Perales-Paton J, De Cubas AA, Inglada-Perez L, Matias-Guiu X, Capel I, Bella M, Lerma E, Riesco-Eizaguirre G, Santisteban P, Maravall F, Mauricio D, Al-Shahrour F, Robledo M (2015) MicroRNA deep-sequencing reveals master regulators of follicular and papillary thyroid tumors. Mod Pathol 28:748–757.CrossRefPubMed
30.
Chruścik A, Lam AK (2015) Clinical pathological impacts of microRNAs in papillary thyroid carcinoma: a crucial review. Exp Mol Pathol 99:393–398.CrossRefPubMed
31.
Sun Y, Yu S, Liu Y, Wang F, Liu Y, Xiao H (2013) Clinical study expression of miRNAs in papillary thyroid carcinomas is associated with BRAF mutation and clinicopathological features in Chinese patients. Int J Endocrinol. doi: 10.​1155/​2013/​128735
32.
Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM, Fusco A (2007) MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27 Kip1 protein levels and cell cycle. Endocr Relat Cancer 14:791–798.CrossRefPubMed
33.
Pacifico F, Crescenzi E, Mellone S, Iannetti A, Porrino N, Liguoro D, Moscato F, Grieco M, Formisano S, Leonardi A (2010) Nuclear factor-kB contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a. J Clin Endocrinol Metab 95:1421–1430.CrossRefPubMed
34.
Zhang Z, Liu Z-B, Ren W-M, Ye X-G, Zhang Y-Y (2012) The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. Int J Mol Med 30:856–862.PubMed
35.
Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN (2014) MicroRNA profile of poorly differentiated thyroid carcinomas—new diagnostic and prognostic insights. J Mol Endocrinol 52:181–189.PubMedCentralCrossRefPubMed
36.
Hudson J, Duncavage E, Tamburrino A, Salerno P, Xi L, Raffeld M, Moley J, Chernock RD (2013) Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. Exp Mol Pathol 95:62–67.PubMedCentralCrossRefPubMed
37.
Gundara JS, Ting Zhao J, Gill AJ, Clifton-Bligh R, Robinson BG, Delbridge L, Sidhu SB, Professor Stan Sidhu CB, Gundara MBBS JS, Zhao JT, Gill AJ, Clifton-Bligh R, Robinson BG, Delbridge L, Sidhu SB (2012) Nodal metastasis microRNA expression correlates with the primary tumour in MTC. ANZ J Surg 84:235–239.CrossRefPubMed
38.
Santarpia L, Calin GA, Adam L, Ye L, Fusco A, Giunti S, Thaller C, Paladini L, Zhang X, Jimenez C, Trimarchi F, El-Naggar AK, Gagel RF (2013) A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr Relat Cancer 20:809–823.CrossRefPubMed
39.
Duan L, Hao X, Liu Z, Zhang Y, Zhang G (2014) MiR-129-5p is down-regulated and involved in the growth, apoptosis and migration of medullary thyroid carcinoma cells through targeting RET. FEBS Lett 588:1644–1651.CrossRefPubMed
40.
41.
Hé Brant A, Bastien Floor S, Saiselet M, Antoniou A, Desbuleux A, Rengè Re Snyers B, La C, De Saint Aubain N, Leteurtre E, Andry G, Maenhaut C, Luque RM (2014) miRNA expression in anaplastic thyroid carcinomas. PLoS One 9:e103871.CrossRef
42.
Huang H, Luo X, Wu S, Jian B (2015) MiR-99a inhibits cell proliferation and tumorigenesis through targeting mTOR in human anaplastic thyroid cancer. Asian Pac J Cancer Prev 16:4937–4944.CrossRefPubMed
43.
Li X, Abdel-Mageed A, Mondal D, Kandil E (2013) MicroRNA expression profiles in differentiated thyroid cancer, a review. Int J Clin Exp Med 6:74–80.PubMedCentralPubMed
44.
Kanehisa M, Goto S (2000) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 28:
45.
Sheedy F, O’Neill L (2008) Adding fuel to fire: microRNAs as a new class of mediators of inflammation. Ann Rheum Dis Suppl 3:iii50–55.
46.
Chang C-J, Chao C-H, Xia W, Yang J-Y, Xiong Y, Li C-W, Yu W-H, Rehman SK, Hsu JL, Lee H-H, Liu M, Chen C-T, Yu D, Hung M-C (2011) p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13:317–323.PubMedCentralCrossRefPubMed
47.
Watanabe A, Tagawa H, Yamashita J, Teshima K, Nara M, Iwamoto K, Kume M, Kameoka Y, Takahashi N, Nakagawa T, Shimizu N, Sawada K (2011) The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia 25:1324–1334.CrossRefPubMed
48.
Puppin C, Durante C, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese A, Boichard A, Lacroix L, Russo D, Filetti S, Damante G (2014) Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. Endocrine 47:528–536.CrossRefPubMed
49.
Mattick JS, Rinn JL (2015) Discovery and annotation of long noncoding RNAs. Nat Struct Mol Biol 22:5–7.CrossRefPubMed
50.
Zhou Q, Chen J, Feng J, Wang J (2015) Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumour Biol. doi: 10.​1007/​s13277-015-4149-9
51.
Lan X, Zhang H, Wang Z, Dong W, Sun W, Shao L, Zhang T, Zhang D (2015) Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma. Gene 569:109–117.CrossRefPubMed
52.
Zheng H, Wang M, Jiang L, Chu H, Hu J, Ning J, Li B, Wang D, Xu J (2015) BRAF-activated long non-coding RNA modulates papillary thyroid carcinoma cell proliferation through regulating thyroid stimulating hormone receptor. Cancer Res Treat. doi: 10.​4143/​crt.​2015.​118 PubMed
53.
Wang Y, Guo Q, Zhao Y, Chen J, Wang S, Hu J, Sun Y (2014) BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett 8:1947–1952.PubMedCentralPubMed
54.
Lan X, Sun W, Zhang P, He L, Dong W, Wang Z, Liu S, Zhang H (2015) Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance. Tumour Biol. doi: 10.​1007/​s13277-015-4461-4
55.
He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S, Kere J, De La Chapelle A (2009) A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Res 69:625–631.PubMedCentralCrossRefPubMed
56.
He H, Li W, Liyanarachchi S, Jendrzejewski J, Srinivas M, Davuluri R V, Nagy R, De La Chapelle A (2015) Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2. J Clin Endocrinol Metab 100:E164–172.PubMedCentralCrossRefPubMed
57.
Jendrzejewski J, Thomas A, Liyanarachchi S, Eiterman A, Tomsic J, He H, Radomska HS, Li W, Nagy R, Sworczak K, de la Chapelle A (2015) PTCSC3 is involved in papillary thyroid carcinoma development by modulating S100A4 gene expression. J Clin Endocrinol Metab 100:E1370–1377.CrossRefPubMed
58.
Fan M, Li X, Jiang W, Huang Y, Li J, Wang Z (2013) A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells. Exp Ther Med 5:1143–1146.PubMedCentralPubMed
59.
Gutschner T, Hämmerle M, Diederichs S (2013) MALAT1—a paradigm for long noncoding RNA function in cancer. J Mol Med 91:791–801.CrossRefPubMed
60.
Yoon JH, Kim E-K, Young J, Hee K, Moon J (2015) Effectiveness and limitations of core needle biopsy in the diagnosis of thyroid nodules: review of current literature. J Pathol Transl Med 49:230–235.PubMedCentralCrossRefPubMed
61.
Labourier E, Shifrin A, Busseniers AE, Lupo MA, Manganelli ML, Andruss B, Wylie D, Beaudenon-Huibregtse S (2015) Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology. J Clin Endocrinol Metab 100:2743–2750.PubMedCentralCrossRefPubMed
62.
Diaz LA, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32:579–586.CrossRefPubMed
63.
Lee JC, Ting Zhao J, Clifton-Bligh RJ, Gill A, Gundara JS, Ip JC, Glover A, Sywak MS, Delbridge LW, Robinson BG, Sidhu SB (2013) MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer 119:4358–4365.CrossRefPubMed
Metadata
Title
Non-Coding RNAs in Thyroid Cancer
Authors
Ranran Zhang
Heather Hardin
Jidong Chen
Zhenying Guo
Ricardo V. Lloyd
Publication date
01-03-2016
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2016
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-016-9417-8

Other articles of this Issue 1/2016

Endocrine Pathology 1/2016 Go to the issue

OriginalPaper

STK11 Mutation Identified in Thyroid Carcinoma

OriginalPaper

Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism

Report

Amyloid Goiter in a Patient with Progressive Thyromegaly

OriginalPaper

A Unique Case of Mediastinal Teratoma with Mature Pancreatic Tissue, Nesidioblastosis, and Aberrant Islet Differentiation: a Case Report and Literature Review

OriginalPaper

Targeted Next-Generation Sequencing Analysis of a Pendred Syndrome-Associated Thyroid Carcinoma

Report

Malignant Mucous Cells in a Thyroid Aspirate: Looking for a Source
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits